Reported 11 days ago
EU antitrust regulators are examining Novo Holdings' $16.5 billion acquisition of Catalent, seeking feedback from competitors and customers to address potential anti-competitive concerns. This inquiry follows Novo's request for EU approval, aiming to enhance the production of its weight-loss drug Wegovy. The European Commission has set a December 6 deadline for preliminary review, with potential remedies due by November 29. The regulatory process highlights the competitive landscape in the booming obesity treatment market, projected to reach $150 billion by the 2030s.
Source: YAHOO